Abstract
The aim of this study was to analyze the sociodemographic, clinical, immunologic, and risk factors of drug-resistant (>1000 copies/ml) and virologically suppressed (<1000 to <40 copies /ml to target not detected levels) patients at the ART center, Sarojini Naidu Medical College, Agra, North India. A total of 193 patients on first-line antiretroviral therapy were included those were recruited from December 2009 to November 2016. The patients included in this study had a CD4 cell count of ≤ 350 cubic/mm. The details of Demographic, clinical, and social factors were collected in a patient information leaflet and statistically analyzed. After viral load, two groups of patients were observed. The drug-resistant group (N=58) had a viral load ≥1000 copies/ml and virologically suppressed group (N=135) had a viral load <1000 copies/ml to target not detected level. A comparison statement result was presented in both groups of drug-resistant and virologically suppressed patients. Males were observed in the highest frequency (42, 72.41%). The heterosexual mode of transmission was predominant (40, 68.96%, and 98,72.59%). The highest number of married couples and illiterates in the two groups. Tuberculosis was observed in the highest numbers in the two groups. The analysis of socioeconomic factors of North Indian patients will be a concern issue in the demographic profiles of HIV-1 patients. The clinical features, analysis would help clinicians in further therapy implementation, monitoring CD4 and Viral load counts of North Indian patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
Indian Council of Medical Research, Govt.of India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Tajganj, Agra-282004.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
